Onyx Biotec Limited vs Sun Pharmaceutical Industries Limited
A side-by-side comparison of Onyx Biotec Limited (ONYX) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Sun Pharmaceutical Industries Limited leads ONYX vs SUNPHARMA on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth10
- Size & financial health04
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SUNPHARMA takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
ONYX takes 1/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
SUNPHARMA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + []
- − ["Company has a low return on equity of 9.5% over last 3 years.", "Company reported a net loss of ₹0 Cr in its latest financial year."]
- + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
- − ["Stock is trading at 5.05 times its book value"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.